XFOR

X4 Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

3.920

+0.74(23.270%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.9293

Open

3.150

VWAP

3.59

Vol

3.29M

Mkt Cap

112.54M

Low

3.1201

Amount

11.81M

EV/EBITDA(TTM)

Total Shares

167.94M

4.54M

EV/OCF(TTM)

P/S(TTM)

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

1.90M

+237.48%

-4.290

+102.61%

2.27M

+305.71%

-2.990

-44.63%

-2.643

-55.94%

Estimates Revision

The market is revising No Change the revenue expectations for X4 Pharmaceuticals, Inc. (XFOR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 26.45%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+26.45%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast XFOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XFOR is 57.75 USD with a low forecast of 7.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 3.920

Low

7.00

Averages

57.75

High

120.00

Current: 3.920

Low

7.00

Averages

57.75

High

120.00

H.C. Wainwright

Swayampakula Ramakanth

Buy

downgrade

2025-08-13

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

2025-08-13

downgrade

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on X4 Pharmaceuticals to $3.50 from $7 and keeps a Buy rating on the shares. The firm updated the company's model to reflect the Q2 report and private placement expected to close on August 13. The capital raised strengthens the balance sheet and aids in meeting the Hercules Loan covenant obligations, the analyst tells investors in a research note.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$1.5

2025-03-27

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$1.5

2025-03-27

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

2025-03-26

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

2025-03-26

Reiterates

Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$1.5

2025-02-07

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$1.5

2025-02-07

Reiterates

Strong Buy

Reason

Latest data shows the largest indicative borrow rate increases among liquid option names include: Azul (AZUL) 70.69% +1.20, Soho House + Co Inc (SHCO) 1.61% +0.98, X4 Pharmaceuticals (XFOR) 2.32% +0.68, Autobot Holdings (ARBE) 8.92% +0.42, Gorilla Technology Group Inc (GRRR) 35.63% +0.29, Ocugen (OCGN) 2.92% +0.28, Plug Power (PLUG) 8.36% +0.22, Equinor (EQNR) 4.81% +0.21, Hecla Mining (HL) 0.58% +0.20, and SolarEdge (SEDG) 0.83% +0.19.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$1.5

2025-01-14

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$1.5

2025-01-14

Reiterates

Strong Buy

Reason

Stifel

Stephen Willey

Strong Buy

Maintains

$5 → $4

2024-11-14

Reason

Stifel

Stephen Willey

Price Target

$5 → $4

2024-11-14

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on X4 Pharmaceuticals to $4 from $5 and keeps a Buy rating on the shares. Sequentially flat Xolremdi sales would seem to suggest that inventory build, and not new patient starts, likely accounted for most of Q2 reported sales, notes the analyst, who adds that the pace of patient screening/onboarding is "meaningfully slower" than the firm's and Street's expectations. The firm's reduced price target mostly reflects lower FY24 and later Xolremdi estimates and revised financing assumptions, the analyst noted.

See All Ratings

Valuation Metrics

The current forward P/E ratio for X4 Pharmaceuticals Inc (XFOR.O) is -0.34, compared to its 5-year average forward P/E of -2.00. For a more detailed relative valuation and DCF analysis to assess X4 Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.00

Current PE

-0.34

Overvalued PE

-0.54

Undervalued PE

-3.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

113.18

Current PS

2.33

Overvalued PS

356.45

Undervalued PS

-130.09